drugset / Trial / NCT00886756

AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00886756

Phase 1 Completed 48 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This is a Phase I, double-blind, placebo-controlled, randomised within each dose group, single ascending dose study, with the objective to assess the safety, tolerability and pharmacokinetic profile of AZD8529 in healthy Japanese subjects.

Timeline

Start
2009-04
Primary completion
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8529 Other / unclassified Oral

Indications

No indication recorded.